SIHUAN PHARM (00460) surged over 9%, and as of press time, the stock was up 7.69% to HK$1.54 with a trading volume of HK$113 million.

On the news front, SIHUAN PHARM announced that the marketing application for semaglutide injection developed by its non-wholly owned subsidiary Huisheng Biopharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA) for improving blood glucose control in adults with type 2 diabetes.

Additionally, the Phase III clinical trial enrollment for semaglutide injection's weight loss indication has been completed and is currently in the follow-up stage.

It is reported that the diabetes field represents a key strategic focus for Huisheng Biopharmaceutical. The acceptance of this semaglutide injection marketing application by the NMPA marks another significant milestone in the drug's development process, which will help further enhance the core competitiveness of both the group and Huisheng Biopharmaceutical in the diabetes treatment sector.